AF
CGEM icon

Amalgamated Financial’s Cullinan Oncology CGEM Stock Holding History

Amalgamated Financial’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$34K Buy
+3,207
New +$43.3K ﹤0.01% 2572

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Amalgamated Financial's CGEM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cullinan Oncology (CGEM) in Q1 2022: 3,207 shares worth $34K. The stake represents ﹤0.01% of the portfolio and ranks #2572 among its holdings.

82 funds tracked by Wall St. Rank hold CGEM as of Q1 2022.

  • Amalgamated Financial held 3,207 shares of Cullinan Oncology worth $34K as of Q1 2022.
  • Cullinan Oncology was a new Amalgamated Financial position in Q1 2022.
  • Cullinan Oncology made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2572 holding.
  • 82 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.